Loading...
Can initial regimens containing two active drugs and no nucleosides be as good as standard treatments? Two prospective pilot studies involving maraviroc and a boosted protease inhibitor (PI) highlight ongoing concerns about this strategy. Both studies were presented last month at the International AIDS Conference in Washington, DC.
In Study A4001078, sponsored by the maker of maraviroc, 121 treatment-naive patients with CCR5-tropic virus at screening were randomized to receive ritonavir-boosted atazanavir plus either maraviroc (150 mg once daily) or tenofovir/FTC [Mills A et al. Abstract TUAB0102]. Consistent with the 48-week results presented at last year's IAS meeting (JW AIDS Clin Care Aug 15 2011), 96-week outcomes favored the tenofovir/…